Newly developed retatrutide, a dual -action drug targeting simultaneously GLP-1 and GIP receptors, is sparking considerable interest within the healthcare community. Initial clinical studies have https://janaqhyv428313.webbuzzfeed.com/41561797/a-new-possibility-for-body-regulation